Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5988611 | 1.00 | LMNA (0.48) | LMNAHIF1AADRA2AADRA2CKDM4E | |
| SCHEMBL3574615 | 1.00 | LMNA (0.48) | LMNAHIF1AADRA2AADRA2CKDM4E | |
| SCHEMBL13502378 | 1.00 | LMNA (0.48) | LMNAHIF1AADRA2AADRA2CKDM4E | |
| SCHEMBL3580851 | 1.00 | LMNA (0.48) | LMNAHIF1AADRA2AADRA2CKDM4E | |
| SCHEMBL3576484 | 1.00 | LMNA (0.48) | LMNAHIF1AADRA2AADRA2CKDM4E | |
| SCHEMBL14420343 | 1.00 | LMNA (0.48) | LMNAHIF1AADRA2AADRA2CKDM4E | |
| SCHEMBL13502376 | 1.00 | LMNA (0.48) | LMNAHIF1AADRA2AADRA2CKDM4E | |
| SCHEMBL14420348 | 1.00 | LMNA (0.48) | LMNAHIF1AADRA2AADRA2CKDM4E | |
| SCHEMBL5907257 | 1.00 | LMNA (0.48) | LMNAHIF1AADRA2AADRA2CKDM4E | |
| SCHEMBL13502368 | 1.00 | LMNA (0.48) | LMNAHIF1AADRA2AADRA2CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | INNODIA INC. (CA) | 2010-02-25 | — | — | US | disclosed |
| EP-1874287-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF OBESITY AND RELATED SYNDROMES | Innodia Inc. (CA) | 2008-01-09 | — | — | EP | disclosed |
| EP-1858840-A2 | ANALOGS OF 4-HYDROXYISOLEUCINE AND USES THEREOF | Innodia Inc. (CA) | 2007-11-28 | — | — | EP | disclosed |
| WO-2007107008-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF DISORDERS OF FAT METABOLISM AND OBESITY | INNODIA INC. (CA) | 2007-09-27 | — | — | WO | disclosed |
| WO-2006131836-A2 | COMPOUNDS AND COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF OBESITY AND RELATED SYNDROMES | INNODIA INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006120574-A2 | ANALOGS OF 4-HYDROXYISOLEUCINE AND USES THEREOF | INNODIA INC. (CA) | 2006-11-16 | — | — | WO | disclosed |
| US-20060223884-A1 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | INVESTISSEMENT QUEBEC (CA) | 2006-10-05 | — | — | US | disclosed |
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | UNIVERSITE LOUIS PASTEUR STRASBOURG I (FR) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223884-A1 | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes | GPR119, HSD3B1, PC | LMNA 770/4885HIF1A 1006/4885ADRA2A 3074/4885 |
| US-20060199853-A1 | Analogs of 4-hydroxyisoleucine and uses thereof | GPR119, SLC2A1, SLC5A1 | LMNA 964/4885HIF1A 514/4885ADRA2A 3039/4885 |
| US-20100048545-A1 | Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity | LIPC, PC, LIPE | LMNA 1108/4885HIF1A 1590/4885ADRA2A 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.